跳至主要内容
临床试验/EUCTR2021-003280-95-NO
EUCTR2021-003280-95-NO进行中(未招募)1 期

An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)

Ionis Pharmaceuticals, Inc.0 个研究点目标入组 60 人开始时间: 2022年5月12日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 2. Satisfactory completion of the ISIS 678354 CS3 index study (last dose as scheduled at Week 49) with an acceptable safety profile, per Investigator judgement
  • 3. Willing to follow a diet comprising = 20 g fat per day during the study
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 55
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 5

排除标准

  • Have any new condition or worsening of existing condition which in the opinion of the Investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study, including need for treatment with medications disallowed in the index study (ISIS 678354-CS3).

研究者

相似试验

招募中
3 期
An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
NL-OMON51487Ionis Pharmaceuticals, Inc.5
进行中(未招募)
1 期
An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered to Patients with Familial Chylomicronemia Syndrome (FCS)Familial Chylomicronemia Syndrome (FCS)MedDRA version: 20.0Level: PTClassification code 10059183Term: Familial hypertriglyceridaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: LLTClassification code 10020607Term: HyperchylomicronemiaSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2021-003280-95-PTIonis Pharmaceuticals, Inc.60
进行中(未招募)
1 期
An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered to Patients with Familial Chylomicronemia Syndrome (FCS)Familial Chylomicronemia Syndrome (FCS)MedDRA version: 20.0Level: PTClassification code 10059183Term: Familial hypertriglyceridaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: LLTClassification code 10020607Term: HyperchylomicronemiaSystem Organ Class: 100000004861
EUCTR2021-003280-95-NLIonis Pharmaceuticals, Inc.60
招募中
3 期
An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered to Patients with Familial Chylomicronemia Syndrome (FCS)
2023-509029-29-00Ionis Pharmaceuticals Inc.30
进行中(未招募)
3 期
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)Familial Chylomicronemia Syndrome
NCT05130450Ionis Pharmaceuticals, Inc.60